Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 1.00 |
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | THRA | P10827 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362406 | 1.00 | CNR2 (1.00) | CNR2CNR1CYP2C9THRATHRB | |
| Naphthoic Acid SCHEMBL27493013 | 0.95 | CNR2 (0.91) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL247971 | 0.90 | CNR2 (0.80) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL247905 | 0.87 | CNR2 (0.77) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL15995238 | 0.87 | CNR2 (0.79) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL27493012 | 0.86 | CNR2 (0.75) | CNR2CNR1CYP2C9MEN1KMT2A | |
| SCHEMBL250281 | 0.86 | CNR2 (0.74) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL248582 | 0.86 | CNR2 (0.74) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL249236 | 0.86 | CNR2 (0.74) | CNR2CNR1CYP2C9THRATHRB | |
| SCHEMBL27557505 | 0.86 | CNR2 (0.74) | CNR2CNR1CYP2C9MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-01-19 | — | — | US | claimed |
| WO-2013025984-A2 | CANNABINOID RECEPTOR TREATMENTS | TEMPLE UNIVERSITY (US) | 2013-02-21 | — | — | WO | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2305215-A1 | Microemulsions of cannabinoid receptor binding compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| EP-2065033-A1 | Microemulsions of cannabinoid receptor binding compounds | Novartis Ag (CH) | 2009-06-03 | — | — | EP | claimed |
| US-20080279940-A1 | Microemulsions of Cannabinoid Receptor Binding Compounds | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-1858484-A1 | MICROEMULSIONS OF CANNABINOID RECEPTOR BINDING COMPOUNDS | Novartis AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094829-A1 | MICROEMULSIONS OF CANNABINOID RECEPTOR BINDING COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20240082270-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20210121414-A1 | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION OF POLYMERIC NANOPARTICLES FOR TREATING NEUROPATHIC PAIN CAUSED BY PERIPHERAL NERVE COMPRESSION | UNIV SEVILLA (ES) | 2021-04-29 | — | — | US | disclosed |
| EP-2744778-B1 | META-SUBSTITUTED BIPHENYL PERIPHERALLY RESTRICTED FAAH INHIBITORS | UNIV CALIFORNIA (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-19 | — | — | US | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| WO-2005058292-A1 | NEW USE IN GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014355-A1 | CANNABINOID RECEPTOR TREATMENTS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885CYP2C9 786/4885 |
| US-20080279940-A1 | Microemulsions of Cannabinoid Receptor Binding Compounds | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885CYP2C9 1204/4885 |
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | CNR2 86/4885CNR1 35/4885CYP2C9 149/4885 |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885CYP2C9 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.